静脉血栓栓塞症合并与不合并慢性肾脏病患者的结局评估
GARFIELD-VTE是一项前瞻性非干预性国际注册研究,纳入8979例30天内客观确诊的VTE患者,比较中重度CKD(3-5期,n=2055)与轻度/无CKD(1-2期,n=6924)的临床特征、治疗模式和12个月结局。中重度CKD组接受直接口服抗凝药(单用或联合肠外治疗)的比例较低。中重度CKD组全因死亡(aHR 1.44,95%CI 1.21-1.73)、大出血(aHR 1.40,95%CI 1.03-1.90)和复发VTE(aHR 1.40,95%CI 1.10-1.77)风险均显著高于轻度/无CKD组。
要点
- 中重度CKD(3-5期)VTE患者全因死亡风险较轻度/无CKD(1-2期)升高:aHR 1.44(95%CI 1.21-1.73)。
- 中重度CKD组大出血风险升高:aHR 1.40(95%CI 1.03-1.90),复发VTE风险亦升高:aHR 1.40(95%CI 1.10-1.77)。
- 中重度CKD组直接口服抗凝药单用比例27.1% vs 轻度/无CKD组30.9%,联合肠外治疗比例15.5% vs 17.9%。
- 两组仅接受肠外治疗的比例相当:中重度CKD组17.3% vs 轻度/无CKD组18.1%。
- 中重度CKD组女性比例更高(57.1% vs 47.1%),年龄>65岁比例更高(62.2% vs 33.4%)。
适用人群与场景
- 纳入:2014年5月至2017年1月在28个国家415个中心注册的GARFIELD-VTE研究中,30天内客观确诊VTE且有血清肌酐数据的8979例患者。
- 分组:中重度CKD(3-5期,n=2055)vs 轻度/无CKD(1-2期,n=6924),CKD分期由估计肾小球滤过率定义。
- 排除:原文未提及具体排除标准。
诊断标准与关键阈值
- CKD分期依据估计肾小球滤过率,采用Modification of Diet in Renal Disease研究公式计算。
- 轻度/无CKD组:1期2991例,2期3933例;中重度CKD组:3期1650例,4期190例,5期215例。
处置流程与药物剂量
- 中重度CKD组仅接受肠外治疗355例(17.3%),轻度/无CKD组1253例(18.1%)。
- 中重度CKD组直接口服抗凝药单用557例(27.1%),轻度/无CKD组2139例(30.9%)。
- 中重度CKD组直接口服抗凝药联合肠外治疗319例(15.5%),轻度/无CKD组1239例(17.9%)。
- 原文未提及具体药物剂量、给药频次或治疗目标值。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 人群特征:轻度/无CKD组中位年龄57岁(IQR 44-69),中重度CKD组中位年龄70岁(IQR 59-78);女性比例分别为49.4%和57.1%。
- VTE表现分布:中重度CKD组单纯DVT 57.0%、单纯PE 26.6%、PE+DVT 16.4%;轻度/无CKD组分别为58.9%、24.9%、16.2%。
- 主要终点:中重度CKD组较轻度/无CKD组全因死亡aHR 1.44(95%CI 1.21-1.73),大出血aHR 1.40(95%CI 1.03-1.90),复发VTE aHR 1.40(95%CI 1.10-1.77)。
- 原文未提及关键次要终点和不良事件的具体结果。
证据类型、等级与局限
- 证据类型:前瞻性非干预性注册研究(队列研究)。
- 局限性:原文未述局限性。
对床旁实践的改变
- 对于VTE合并中重度CKD(3-5期)患者,应认识到其较轻度/无CKD患者有更高的全因死亡、大出血和复发VTE风险(aHR分别为1.44、1.40、1.40)。
- 中重度CKD组直接口服抗凝药使用比例较低(单用27.1% vs 30.9%,联合肠外15.5% vs 17.9%),提示临床实践中对该人群抗凝策略的选择存在差异。
- 原文未提及具体抗凝药物调整方案或监测建议。
指南或共识出处
- GARFIELD-VTE研究,发表于JAMA Network Open。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Patients with venous thromboembolism (VTE) and concomitant chronic kidney disease (CKD) have been reported to have a higher risk of thrombosis and major bleeding complications compared with patients without concomitant CKD. The use of anticoagulation therapy is challenging, as many anticoagulant medications are excreted by the kidney. Large-scale data are needed to clarify the impact of CKD for anticoagulant treatment strategies and clinical outcomes of patients with VTE.
OBJECTIVE: To compare clinical characteristics, treatment patterns, and 12-month outcomes among patients with VTE and concomitant moderate to severe CKD (stages 3-5) vs patients with VTE and mild to no CKD (stages 1-2) in a contemporary international registry.
DESIGN, SETTING, AND PARTICIPANTS: The Global Anticoagulant Registry in the Field-Venous Thromboembolism (GARFIELD-VTE) study is a prospective noninterventional investigation of real-world treatment practices. A total of 10 684 patients from 415 sites in 28 countries were enrolled in the GARFIELD-VTE between May 2014 and January 2017. This cohort study included 8979 patients (6924 patients with mild to no CKD and 2055 patients with moderate to severe CKD) who had objectively confirmed VTE within 30 days before entry in the registry. Chronic kidney disease stages were defined by estimated glomerular filtration rates. Data were extracted from the study database on December 8, 2018, and analyzed between May 1, 2019, and July 30, 2020.
EXPOSURE: Moderate to severe CKD vs mild to no CKD.
MAIN OUTCOMES AND MEASURES: The primary outcomes were all-cause mortality, recurrent VTE, and major bleeding. Event rates and 95% CIs were calculated and expressed per 100 person-years. Hazard ratios (HRs) were estimated with Cox proportional hazards regression models and adjusted for relevant confounding variables. All-cause mortality was considered a competing risk for other clinical outcomes in the estimation of cumulative incidences.
RESULTS: Of the 10 684 patients with objectively confirmed VTE, serum creatinine data were available for 8979 patients (84.0%). Of those, 4432 patients (49.4%) were female and 5912 patients (65.8%) were White; 6924 patients (77.1%; median age, 57 years; interquartile range [IQR], 44-69 years) were classified as having mild to no CKD, and 2055 patients (22.9%; median age, 70 years; IQR, 59-78 years) were classified as having moderate to severe CKD. Calculations using the equation from the Modification of Diet in Renal Disease study indicated that, among the 6924 patients with mild to no CKD, 2991 patients had stage 1 CKD, and 3933 patients had stage 2 CKD; among the 2055 patients with moderate to severe CKD, 1650 patients had stage 3 CKD, 190 patients had stage 4 CKD, and 215 patients had stage 5 CKD. The distribution of VTE presentation was comparable between groups. In total, 1171 patients (57.0%) with moderate to severe CKD and 4079 patients (58.9%) with mild to no CKD presented with deep vein thrombosis alone, 547 patients (26.6%) with moderate to severe CKD and 1723 patients (24.9%) with mild to no CKD presented with pulmonary embolism alone, and 337 patients (16.4%) with moderate to severe CKD and 1122 patients (16.2%) with mild to no CKD presented with both pulmonary embolism and deep vein thrombosis. Compared with patients with mild to no CKD, patients with moderate to severe CKD were more likely to be female (3259 women [47.1%] vs 1173 women [57.1%]) and older than 65 years (2313 patients [33.4%] vs 1278 patients [62.2%]). At baseline, the receipt of parenteral therapy alone was comparable between the 2 groups (355 patients [17.3%] with moderate to severe CKD vs 1253 patients [18.1%] with mild to no CKD). Patients with moderate to severe CKD compared with those with mild to no CKD were less likely to be receiving direct oral anticoagulant therapy, either alone (557 patients [27.1%] vs 2139 patients [30.9%]) or in combination with parenteral therapy (319 patients [15.5%] vs 1239 patients [17.9%]). Patients with moderate to severe CKD had a higher risk of all-cause mortality (adjusted hazard ratio [aHR], 1.44; 95% CI, 1.21-1.73), major bleeding (aHR, 1.40; 95% CI, 1.03-1.90), and recurrent VTE (aHR, 1.40; 95% CI, 1.10-1.77) than patients with mild to no CKD.
CONCLUSIONS AND RELEVANCE: In this study of patients with VTE, the presence of moderate to severe CKD was associated with increases in the risk of death, VTE recurrence, and major bleeding compared with the presence of mild to no CKD.
参考来源
- Goto S, Haas S, Ageno W, et al. Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease. JAMA Netw Open. 2020. PMID: 33112399. doi:10.1001/jamanetworkopen.2020.22886
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。